Roche Holding AG
RHHBYDrugs in Pipeline
440
Phase 3 Programs
274
Upcoming Catalysts
110
Next Catalyst
Apr 30, 2026
TomorrowMarket Overview
Stock performance and key metrics
113 upcoming, 7 past
Vincristine Phase 3 Results Expected
Primary completion for Vincristine trial (NCT03274492) in Diffuse Large B-Cell Lymphoma
Met primary endpoint; significantly reduced relapses versus standard of care to approximately one every 17 years
SourcePrednisone Phase 3 Results Expected
Primary completion for Prednisone trial (NCT03274492) in Diffuse Large B-Cell Lymphoma
SourcePolatuzumab Vedotin Phase 3 Results Expected
Primary completion for Polatuzumab Vedotin trial (NCT03274492) in Diffuse Large B-Cell Lymphoma
SourceCyclophosphamide Phase 3 Results Expected
Primary completion for Cyclophosphamide trial (NCT03274492) in Diffuse Large B-Cell Lymphoma
SourceRituximab Phase 3 Results Expected
Primary completion for Rituximab trial (NCT03274492) in Diffuse Large B-Cell Lymphoma
SourceDoxorubicin Phase 3 Results Expected
Primary completion for Doxorubicin trial (NCT03274492) in Diffuse Large B-Cell Lymphoma
Failed to demonstrate muscle-building efficacy; Phase III trials will not be initiated
SourceOther
Roche announces the appointment of Mark Dawson, M.D., Ph.D., as Head of Roche Pharma Research and Early Development, effective 1 May 2026, with a concurrent position on the Enlarged Corporate Executive Committee.
106 more catalysts beyond 14 days
Start a 48h free trial to see all upcoming catalysts
Paclitaxel
Ovarian Cancer
RO7204239
Obesity
trastuzumab (Herceptin®)
Breast Cancer
mycophenolate mofetil [CellCept]
Myasthenia Gravis Generalised
Lenvatinib
Unresectable Hepatocellular Carcinoma
Eculizumab
Paroxysmal Nocturnal Hemoglobinuria
Entecavir
Pediatric Immuno-Tolerant Chronic Hepatitis B
Mosunetuzumab
Non-Hodgkin Lymphoma
Prasinezumab
Parkinsons Disease
Dalcetrapib (RO4607381)
Coronary Heart Disease
FEC Chemotherapy
Breast Cancer
Darbepoetin alfa
Anemia
Interferon beta-1a
Relapsing Multiple Sclerosis
Carboplatin
Breast Cancer
Etoposide
Small Cell Lung Carcinoma
Mycophenolate Mofetil
Pemphigus Vulgaris
Folic acid or folate
Rheumatoid Arthritis
Evidence-based medical care for Acute Coronary Syndrome
Coronary Heart Disease
Vincristine
Non-Hodgkin's Lymphoma
Tiragolumab
Small Cell Lung Cancer
methoxy polyethylene glycol-epoetin beta [RO0503821, Mircera]
Anemia
methylprednisolone
Rheumatoid Arthritis
Vamikibart
Diabetic Macular Edema
Ribavirin
Hepatitis C, Chronic
Factor VIII (FVIII)
Hemophilia A
Pralsetinib
RET-fusion Non Small Cell Lung Cancer
Cabozantinib
Carcinoma, Non-Small-Cell Lung
Anti-VEGF Therapy
Neovascular Age-related Macular Degeneration
epoetin alfa or beta
Anemia
Zidovudine
HIV Infections
Remdesivir
COVID-19 Pneumonia
Polatuzumab Vedotin
Non-Hodgkin's Lymphoma
r-HuEPO
Anemia
Fingolimod
Relapsing-Remitting Multiple Sclerosis
Teriflunomide
Relapsing Multiple Sclerosis
Sefaxersen (RO7434656)
Primary IgA Nephropathy
tocilizumab [RoActemra]
Rheumatoid Arthritis
Standard DMARDs (Disease Modifying Anti Rheumatic Drugs)
Rheumatoid Arthritis
Tocilizumab (TCZ)
Rheumatoid Arthritis
Valganciclovir CMV Prophylaxis
Cytomegalovirus Infections
Neo-adjuvant chemotherapy
Breast Cancer
Enfuvirtide
HIV Infections
Pertuzumab
Breast Cancer
Taxane-based chemotherapy
Breast Cancer
Cyclosporine
Renal Transplantation
23-PPV
Multiple Sclerosis, Relapsing-Remitting
FAP IL2V
Cancer
Alimta or Taxotere
Non-Small Cell Lung Cancer
Oxaliplatin 130 mg/m^2
Colorectal Cancer
Non-steroidal anti-inflammatory drugs (NSAIDs)
Juvenile Idiopathic Arthritis
chlorambucil
Lymphocytic Leukemia, Chronic
5-Fluoruracil
Gastric Cancer
Giredestrant
Endometrial Cancer
Oseltamivir IV
Influenza
Sorafenib
Carcinoma, Hepatocellular
Interferon alfa 2a [Roferon]
Renal Cell Cancer
Disease-modifying anti-rheumatic drugs
Rheumatoid Arthritis
Becavizumab
Hepatocellular Carcinoma
Azathioprine
Rheumatoid Arthritis
Letrozole
Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
Crizotinib
Neoplasms
Bitopertin
Beta-Thalassemia
Pegylated Interferon Alfa-2a
Chronic Myelogenous Leukemia
Pembrolizumab
Non-small Cell Lung Cancer (NSCLC)
Divarasib
Non-Small Cell Lung Cancer
Rituximab SC
Non-Hodgkin's Lymphoma
saquinavir [Invirase]
HIV Infections
Optimized background antiretroviral regimen (OB)
HIV Infections
Permitted DMARDs
Rheumatoid Arthritis
Adalimumab
Ulcerative Colitis
exenatide
Diabetes Mellitus Type 2
Ocrelizumab IV
Relapsing Multiple Sclerosis
bitopertin [RO4917838] level 1
Schizophrenia
MTX
Rheumatoid Arthritis
Antipsychotics
Schizophrenia
Pegylated interferon (PEG-IFN) alfa-2a, 180 mcg
Hepatitis B, Chronic
Dacarbazine
Malignant Melanoma
rFVIIa
Hemophilia A
Taxotere
Breast Cancer
Fluoropyrimidine-based Chemotherapy
Colorectal Cancer
CDK4/6i
Breast Cancer
PDS Implant Pre-Filled with 100 mg/mL Ranibizumab
Diabetic Retinopathy
CMF
Breast Cancer
Doxorubicin
Diffuse Large B-Cell Lymphoma, Lymphoma Follicular
Stavudine
HIV Infections
temozolomide
Glioblastoma Multiforme
Ganciclovir
Cytomegalovirus Retinitis
tocilizumab SC
Rheumatoid Arthritis
Lamivudine
HIV Infections
PDS Implant with Ranibizumab 100 mg/mL
Neovascular Age-Related Macular Degeneration
Erlotinib
Non-Squamous Non-Small Cell Lung Cancer
satralizumab
Neuromyelitis Optica Spectrum Disorder
MMF
Lupus Nephritis
interferon-a-2a
Lymphoma
Baloxavir Marboxil
Influenza
TRO19622
Amyotrophic Lateral Sclerosis
XELOX
Colorectal Cancer
Standard adjuvant chemotherapy
Breast Cancer
DMARD
Rheumatoid Arthritis
Sunitinib
Renal Cell Carcinoma
Mycophenolate Mofetil 2 g/Day
Pemphigus Vulgaris (PV)
Lebrikizumab
Asthma
Faricimab
Wet Macular Degeneration
Pegylated-interferon Alfa-2a
Hepatitis C, Chronic
Standard chemotherapy
Breast Cancer
von Willebrand Factor (VWF) Concentrates
Von Willebrand Disease, Type 3
Oral Corticosteroids
Rheumatoid Arthritis
Prednisone
Lymphoma
valganciclovir [Valcyte]
Cytomegalovirus Infections
Acetaminophen/ Paracetamol
Childhood Idiopathic Nephrotic Syndrome
Corticosteroids
Breast Cancer
Antihistamine
Multiple Sclerosis
Lapatinib
Breast Cancer
epoetin
Anemia
Human Coagulation Factor VIII
Hemophilia A
Nab-paclitaxel
Non-Small-Cell Lung
fusidic acid [Verutex]
Non-Small Cell Lung Cancer
Risdiplam
Muscular Atrophy, Spinal
Ocrelizumab
Multiple Sclerosis
Pegylated Interferon (PEG-IFN) alfa-2a
Hepatitis D, Chronic
Enzalutamide
Prostatic Neoplasms, Castration-Resistant
oseltamivir
Influenza, Human
Gemcitabine (Chemotherapy)
Ovarian Cancer
Second-Line Chemotherapy
Non-Squamous Non-Small Cell Lung Cancer
Nelfinavir mesylate
HIV Infections
Zalcitabine
HIV Infections
Efavirenz
HIV Infections
Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody
Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer
Etrozulimab
Ulcerative Colitis
Vinflunine
Bladder Cancer
Neoral
Kidney Transplantation
Gantenerumab
Alzheimer's Disease
PDS Implant filled with 100 mg/mL Ranibizumab
Neovascular Age-Related Macular Degeneration
Fulvestrant
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
anti-IL-2R
Kidney Transplantation
Endocrine Therapy of Physician's Choice
Early Breast Cancer
Delavirdine mesylate
HIV Infections
Chemotherapy (Induction Period)
Non-Hodgkin's Lymphoma
Fludarabine
Lymphocytic Leukemia, Chronic
tenofovir
Hepatitis D, Chronic
RO0503821 (1x/2 Weeks)
Anemia
pioglitazone
Diabetes Mellitus Type 2
Olesoxime
Muscular Atrophy, Spinal
Riluzole
Amyotrophic Lateral Sclerosis
Astegolimab
Chronic Obstructive Pulmonary Disease (COPD)
Vinorelbine
Non-Small Cell Lung Cancer
bitopertin [RO4917838]
Schizophrenia
Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody
Squamous Non-Small Cell Lung Cancer
Mycophenolate mofetil (MMF)
Lupus Nephritis
5-Fluorouracil
Gastric Cancer
cyclosporine A (CsA)
Heart Transplantation
Bendamustine
Chronic Lymphocytic Leukemia
Platinum chemotherapy (cisplatin or carboplatin)
Non-Squamous Non-Small Cell Lung Cancer
Irinotecan
Colorectal Cancer
Pertuzumab IV
Early Breast Cancer
Venetoclax
Chronic Lymphocytic Leukemia
RO7234292 (RG6042)
Huntington Disease
Epirubicin
Breast Cancer
Regorafenib
Colorectal Cancer
Tacrolimus
Primary Membranous Nephropathy
trastuzumab [Herceptin]
Breast Cancer
Acitretin
HIV Infections
Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP)
Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma
Ranibizumab (10 mg/mL)
Neovascular Age-related Macular Degeneration
insulin glargine
Diabetes Mellitus Type 2
Lenalidomide
Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Nonbiologic DMARDs of investigator's choice
Rheumatoid Arthritis
Tocilizumab 162 mg
Rheumatoid Arthritis
Optional Endocrine Therapy of Investigator's Choice
Metastatic Breast Cancer
Epoetin alfa
Anemia
5-Fluorouracil (5-FU)
Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
Leucovorin calcium
Colorectal Cancer
5 FU
Neoplasms
Intravitreal Ranibizumab 0.5 mg Injection
Diabetic Macular Edema
Treatment of physician's choice
Breast Cancer
Oxaliplatin
Colorectal Cancer
montelukast [Singulair]
Asthma
Non-Biologic DMARDs
Rheumatoid Arthritis
rHuPH20
Non-Small Cell Lung Cancer
Tociluzumab
Relapsed or Refractory Follicular Lymphoma
Infliximab
Ulcerative Colitis
Fluorouracil
Gastric Cancer
Vemurafenib
Melanoma
Ipatasertib
Triple-Negative Breast Cancer
Ranibizumab
Diabetic Macular Edema
Emicizumab
Hemophilia A
Afimkibart
Crohns Disease
Docetaxel
Non-Small Cell Lung Cancer
tocilizumab [RoActemra/Actemra]
Rheumatoid Arthritis
Trastuzumab
Breast Cancer
Rituximab
Rheumatoid Arthritis
Atezolizumab
Carcinoma, Hepatocellular
Methoxy polyethylene glycol-epoetin beta (C.E.R.A.)
Anemia
Mircera
Anemia
erlotinib [Tarceva]
Non-Small Cell Lung Cancer
Saquinavir
HIV Infections
Obinutuzumab
Chronic Lymphocytic Leukemia (CLL)
rituximab [MabThera/Rituxan]
Rheumatoid Arthritis
Cyclophosphamide
Breast Cancer
liposomal doxorubicin
Ovarian Cancer
Omalizumab
Nasal Polyps
csDMARDs
Rheumatoid Arthritis
pertuzumab [Perjeta]
Breast Cancer
tocilizumab
Rheumatoid Arthritis
bevacizumab [Avastin]
Non-Squamous Non-Small Cell Lung Cancer
ritonavir
HIV Infections
Etrolizumab
Crohn Disease
leucovorin
Colorectal Cancer
Epoetin beta
Anemia
Lurbinectedin
Small-Cell Lung Cancer
taspoglutide
Diabetes Mellitus Type 2
Bevacizumab
Carcinoma, Hepatocellular
Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody
Triple-Negative Breast Cancer
Ibandronate
Post-Menopausal Osteoporosis
methotrexate
Rheumatoid Arthritis
Entrectinib
Solid Tumors
peginterferon alfa-2a [Pegasys]
Hepatitis B, Chronic
Methoxy Polyethylene Glycol-Epoetin Beta
Anemia
mycophenolate mofetil (CellCept)
Myasthenia Gravis, Generalized
Onartuzumab
Glioblastoma
Pirfenidone
Lung Diseases, Interstitial
Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
Carcinoma, Non-Squamous Non-Small Cell Lung
Capecitabine
Gastric Cancer
Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC)
Early Breast Cancer
Trastuzumab IV
HER2-positive Early Breast Cancer
Other Combination Anti-Cancer Therapies
Solid Tumors
Valganciclovir
Cytomegalovirus Infections
Filgrastim
Triple-negative Breast Cancer
methoxy polyethylene glycol-epoetin beta [Mircera]
Anemia
Herceptin
Breast Cancer
Trastuzumab Emtansine
Breast Cancer
Gemcitabine
Pancreatic Cancer
Fenebrutinib
Relapsing Multiple Sclerosis
Dexamethasone
Idiopathic Thrombocytopenic Purpura
Glofitamab
Diffuse Large B-cell Lymphoma
Alectinib
Non-Small Cell Lung Cancer
capecitabine [Xeloda]
Colorectal Cancer
Peginterferon alfa-2a
Carcinoma, Hepatocellular
Cladribine
Lymphocytic Leukemia, Chronic
metformin
Diabetes Mellitus Type 2
ibandronate [Bonviva/Boniva]
Post-Menopausal Osteopenia
Trontinemab
Alzheimers Disease
Aflibercept
Diabetic Macular Edema
RO7239361
Duchenne Muscular Dystrophy
Sitagliptin
Diabetes Mellitus Type 2
aleglitazar
Diabetes Mellitus Type 2
Alectnib
Carcinoma, Non-Small-Cell Lung
Chemotherapy
Non-Small Cell Lung Cancer
Inavolisib
Breast Cancer
Leucovorin (LV)
Colorectal Cancer
CHOP
Lymphoma, Large B-Cell, Diffuse
rituximab [MabThera]
Rheumatoid Arthritis
RO4917838
Schizophrenia
Baseline Treatment
Neuromyelitis Optica (NMO)
Acetaminophen/Paracetamol
Systemic Lupus Erythematosus
Phesgo
Locally Advanced or Metastatic Breast Cancer
Fludarabine Phosphate
Chronic Lymphocytic Leukemia
methoxy polyethylene glycol-epoetin beta [C.E.R.A.]
Anemia
Pemetrexed
Carcinoma, Non-Small-Cell Lung
Ortho-Novum® 1/35
Rheumatoid Arthritis
PEGASYS
Hepatitis C, Chronic
Cisplatin
Nasopharyngeal Cancer
orlistat [Xenical]
Obesity
aleglitazar+metformin
Diabetes Mellitus Type 2
dalcetrapib
Coronary Heart Disease
Palbociclib
Breast Cancer
Tiragolumab and Atezolizumab
Cancer
Cobimetinib
Melanoma
DMARDs
Rheumatoid Arthritis
MabThera/Rituxan
Rheumatoid Arthritis
RO7234292
Huntingtons Disease
Onartuzumab [MetMAb]
Non-Small Cell Lung Cancer
epoetin beta [NeoRecormon]
Anemia
Crovalimab
Atypical Hemolytic Uremic Syndrome
Dual Integrin Antagonist
Asthma
RO4917523 1.5 mg
Major Depressive Disorder
Semaglutide
Type 2 Diabetes Mellitus
Atezolizumab Cohort 7
Solid Tumors
boceprevir
Hepatitis C, Chronic
Abemaciclib
Ovarian Cancer
RO7247669
Melanoma
enfuvirtide [Fuzeon]
HIV Infections
Tiragolumab and Atezolizumab IV FDC
PD-L1-selected Solid Tumors
Ro 24-7429
Sarcoma, Kaposi
RG7314
Autism Spectrum Disorder
Tociliuzumab
COVID-19 Pneumonia
TCS Cream
Atopic Dermatitis
Tobemstomig
Urothelial Cancer
antibody induction
Kidney Transplantation
Onartuzumab (MetMAb)
Gastric Cancer
Standard antipsychotic therapy
Schizophrenia
RO6864018
Hepatitis B, Chronic
RO5093151
Hypertension, Glaucoma, Open-Angle
Induction- PF-06480605 50 mg SC Q4W
Moderate to Severe Ulcerative Colitis
RO7268489
Progressive Multiple Sclerosis
LABA
Asthma
vismodegib
Basal Cell Carcinoma
RO4588161
Hepatitis C, Chronic
PEGPH20
Pancreatic Adenocarcinoma
FOLFIRI
Colorectal Cancer
Olaparib
Cancer of Unknown Primary Site
RO4998452
Diabetes Mellitus Type 2
RO4602522
Alzheimer's Disease
ribavirin [Copegus]
Hepatitis C, Chronic
Everolimus
Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer
Zifibancimig
Macular Degeneration
Anastrozole
Early Breast Cancer
Mericitabine
Hepatitis C
Lomustine
Glioblastoma
Induction Chemotherapy
Breast Cancer
AT-527
COVID-19
Olesoxime (TRO19622)
Chemotherapy-Induced Peripheral Neuropathy
capecitabine (Xeloda®)
Breast Cancer
Standard platinum-based chemotherapy
Non-Small Cell Lung Cancer
SGN-LIV1A
Metastatic Breast Cancer
Actos
Diabetes Mellitus Type 2
bevacizumab (Avastin)
Liver Cancer
First line chemotherapy
Mantle Cell Lymphoma
Folic Acid
Rheumatoid Arthritis
Erythropoietin Beta
Myelodysplastic Syndromes
PRM-151
Idiopathic Pulmonary Fibrosis
RO7126209
Alzheimers Disease
Metronidazole Actavis
Non-Squamous Non-Small Cell Lung Cancer
Tominersen
Huntington Disease
RO5027838
Diabetes Mellitus Type 2
RO7490677
Primary Myelofibrosis
Mycophenolate Mofetil/Mycophenolic Acid
Lupus Nephritis
RO5313534
Alzheimer's Disease
RO6889450
Schizophrenia, Schizoaffective Disorder
Epidoxorubicin
Breast Cancer
Balovaptan
Stress Disorders, Post-Traumatic
Carboplatin-based chemotherapy
Non-Small Cell Lung Cancer
Pegylated Interferon (Peginterferon) Alfa-2a
Hepatitis B, Chronic
Pravastatin
Dyslipidemia
Lomvastomig
Advanced or Metastatic Esophageal Squamous Cell Carcinoma
RG3421 120mg
Psoriasis
Standard taxane therapy
Breast Cancer
Doxycline
Non-Small Cell Lung Cancer
Ifosfamide
Mature B-Cell Non-Hodgkin Lymphoma
obinutuzumab (RO5072759)
Non-Hodgkin's Lymphoma
Iberdomide
Multiple Myeloma
RO5083945
Non-Squamous Non-Small Cell Lung Cancer
GC33
Carcinoma, Hepatocellular
fluorouracil (5FU)
Colorectal Cancer
RO5217790
Cervical Intraepithelial Neoplasia
RO4917523
Fragile X Syndrome
pralsetinib (BLU-667)
RET-altered Non Small Cell Lung Cancer
5-FU
Colorectal Cancer
ibandronate [Bondronat]
Pain; Bone Neoplasms; Neoplasm Metastasis
Mosunetuzumab (SC)
Follicular Lymphoma
RO4876904
Diabetes Mellitus Type 2
Crenezumab
Alzheimer Disease
Cevostamab
Multiple Myeloma
RO4917523 0.5 mg
Fragile X Syndrome
Erlotinib, escalating dose
Pancreatic Cancer
eloxatin
Colorectal Cancer
ANA598
HCV Infection
Copegus
Hepatitis C, Chronic
N-acetylcysteine
Idiopathic Pulmonary Fibrosis
OpRegen
Age-Related Macular Degeneration
Basmisanil
Schizophrenia
TRO40303
Acute Myocardial Infarctus
RG7774
Diabetic Retinopathy
RO7795081
Obesity or Overweight
RO5190591 (Danoprevir)
Hepatitis C, Chronic
RO4995819
Major Depressive Disorder
Abiraterone
Metastatic Castration-Resistant Prostate Cancer
P38 Inhibitor (4) 150mg
Rheumatoid Arthritis
Forimtamig
Relapsed or Refractory Multiple Myeloma
Inhaled corticposteroids (ICS)
Asthma
Experimental
Diabetic Neuropathy
fotemustine
Glioblastoma Multiforme
Investigator's choice of anti-cancer treatment (except immunotherapy)
Breast Cancer
Sham Procedure
Neovascularization, Choroidal
Atezolizumab [TECENTRIQ]
Lymphoma
Optimized Background ARVs
HIV Infections
Trastuzumab emtansine [Kadcyla]
Breast Cancer
Abacavir sulfate
HIV Infections
RO4905417
Coronary Heart Disease, Graft Occlusion, Vascular
Taxane (docetaxel or paclitaxel)
Breast Cancer
RO5190591
Hepatitis C, Chronic
Temozolomide (TMZ)
High Grade Glioma
Sildenafil
Idiopathic Pulmonary Fibrosis
NXT007
Hemophilia A
RO5459072
Sjogren's Syndrome
RAR Gamma
Emphysema
Alogabat
Angelman Syndrome
89Zr-Df-IAB22M2C
Non-Hodgkins Lymphoma
beta-lactam
Soft Tissue Infections
RO5185426
Malignant Melanoma
Mosunetuzumab Intravenous (IV)
Diffuse Large B-cell Lymphoma
Englumafusp alfa
Lymphoma, Non-Hodgkin
Rituxumab
B-cell Non-Hodgkin Lymphoma
SSRI
Obsessive-Compulsive Disorder
RO7269162
Alzheimer's Disease
Polatuzumab vedotin (Liquid)
Lymphoma
Ribociclib
Breast Cancer
RO7247669 2100 mg
Melanoma
Ocrelizumab Test Formulation
Multiple Sclerosis
Xeloda
Breast Cancer
C.E.R.A.
Anemia
cetuximab
Multiple Myeloma, Neoplasms
Taspoglutide 20mg
Diabetes Mellitus Type 2
Mosunetuzumab (IV)
B-cell Non-Hodgkin Lymphoma
RO6958688
Carcinoma, Non-Small-Cell Lung
Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody
Breast Neoplasms
Trastuzumab emtansine [Kadcyla] 3.0 mg/kg
Metastatic Breast Cancer
RO4929097
Non-Squamous Non-Small Cell Lung Cancer
P38 Inhibitor (4)
Rheumatoid Arthritis
Ceftriaxone
Pneumonia, Bacterial
Didanosine
HIV Infections
Folinic Acid
Rectal Cancer
Levofolinic acid
Colorectal Cancer
Autogene Cevumeran
Muscle-invasive Urothelial Carcinoma
danoprevir + ritonavir
Hepatitis C, Chronic
Epothilone D
Breast Cancer
Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC)
HER2-Positive Early Breast Cancer
Interferon alfa-2a
Renal Cell Cancer
ZN-A-1041
Advanced Solid Tumors
Axitinib
Renal Cell Carcinoma
Nucleos(t)ide (NUC)
Hepatitis B, Chronic
GK Activator (2)
Diabetes Mellitus Type 2
Second line chemotherapy
Breast Cancer
RG1662
Down Syndrome
Rituximab IV
Lymphoma, Large B-Cell, Diffuse
Fulvestrant or an Aromatase Inhibitor (Physician Choice)
Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer
RO7046015
Parkinson's Disease
Atezolizumab (MPDL3280A) [TECENTRIQ]
Lymphoma, Follicular
Aromatase Inhibitor
Breast Cancer
Diphenhydramine hydrochloride (HCl)
Lupus Nephritis
Hormonal Therapy
Breast Cancer
DPP-IV Inhibitor
Diabetes Mellitus Type 2
Enfortumab Vedotin
Urothelial Carcinoma
PEGASYS [peginterferon alfa-2a]
Hepatitis B, Chronic
MSTT1041A
Asthma
RO7017773
Autism Spectrum Disorder (ASD)
RO 205-2349
Diabetes
Danoprevir
Hepatitis C, Chronic
Bevacizumab 15 mg/kg
Advanced Liver Cancers
RO5024048
Hepatitis C, Chronic
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Paclitaxel | Phase 3 | Ovarian Cancer | - | - |
RO7204239 | Phase 3 | Obesity | - | - |
trastuzumab (Herceptin®) | Phase 3 | Breast Cancer | - | - |
mycophenolate mofetil [CellCept] | Phase 3 | Myasthenia Gravis Generalised | - | - |
Lenvatinib | Phase 3 | Unresectable Hepatocellular Carcinoma | - | - |
Eculizumab | Phase 3 | Paroxysmal Nocturnal Hemoglobinuria | - | - |
Entecavir | Phase 3 | Pediatric Immuno-Tolerant Chronic Hepatitis B | - | - |
Mosunetuzumab | Phase 3 | Non-Hodgkin Lymphoma | - | - |
Prasinezumab | Phase 3 | Parkinsons Disease | - | - |
Dalcetrapib (RO4607381) | Phase 3 | Coronary Heart Disease | - | - |
FEC Chemotherapy | Phase 3 | Breast Cancer | - | - |
Darbepoetin alfa | Phase 3 | Anemia | - | - |
Interferon beta-1a | Phase 3 | Relapsing Multiple Sclerosis | - | - |
Carboplatin | Phase 3 | Breast Cancer | - | - |
Etoposide | Phase 3 | Small Cell Lung Carcinoma | - | - |
Mycophenolate Mofetil | Phase 3 | Pemphigus Vulgaris | - | - |
Folic acid or folate | Phase 3 | Rheumatoid Arthritis | - | - |
Evidence-based medical care for Acute Coronary Syndrome | Phase 3 | Coronary Heart Disease | - | - |
Vincristine | Phase 3 | Non-Hodgkin's Lymphoma | - | - |
Tiragolumab | Phase 3 | Small Cell Lung Cancer | - | - |
methoxy polyethylene glycol-epoetin beta [RO0503821, Mircera] | Phase 3 | Anemia | - | - |
methylprednisolone | Phase 3 | Rheumatoid Arthritis | - | - |
Vamikibart | Phase 3 | Diabetic Macular Edema | - | - |
Ribavirin | Phase 3 | Hepatitis C, Chronic | - | - |
Factor VIII (FVIII) | Phase 3 | Hemophilia A | - | - |
Pralsetinib | Phase 3 | RET-fusion Non Small Cell Lung Cancer | - | - |
Cabozantinib | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
Anti-VEGF Therapy | Phase 3 | Neovascular Age-related Macular Degeneration | - | - |
epoetin alfa or beta | Phase 3 | Anemia | - | - |
Zidovudine | Phase 3 | HIV Infections | - | - |
Remdesivir | Phase 3 | COVID-19 Pneumonia | - | - |
Polatuzumab Vedotin | Phase 3 | Non-Hodgkin's Lymphoma | - | - |
r-HuEPO | Phase 3 | Anemia | - | - |
Fingolimod | Phase 3 | Relapsing-Remitting Multiple Sclerosis | - | - |
Teriflunomide | Phase 3 | Relapsing Multiple Sclerosis | - | - |
Sefaxersen (RO7434656) | Phase 3 | Primary IgA Nephropathy | - | - |
tocilizumab [RoActemra] | Phase 3 | Rheumatoid Arthritis | - | - |
Standard DMARDs (Disease Modifying Anti Rheumatic Drugs) | Phase 3 | Rheumatoid Arthritis | - | - |
Tocilizumab (TCZ) | Phase 3 | Rheumatoid Arthritis | - | - |
Valganciclovir CMV Prophylaxis | Phase 3 | Cytomegalovirus Infections | - | - |
Neo-adjuvant chemotherapy | Phase 3 | Breast Cancer | - | - |
Enfuvirtide | Phase 3 | HIV Infections | - | - |
Pertuzumab | Phase 3 | Breast Cancer | - | - |
Taxane-based chemotherapy | Phase 3 | Breast Cancer | - | - |
Cyclosporine | Phase 3 | Renal Transplantation | - | - |
23-PPV | Phase 3 | Multiple Sclerosis, Relapsing-Remitting | - | - |
FAP IL2V | Phase 3 | Cancer | - | - |
Alimta or Taxotere | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Oxaliplatin 130 mg/m^2 | Phase 3 | Colorectal Cancer | - | - |
Non-steroidal anti-inflammatory drugs (NSAIDs) | Phase 3 | Juvenile Idiopathic Arthritis | - | - |
chlorambucil | Phase 3 | Lymphocytic Leukemia, Chronic | - | - |
5-Fluoruracil | Phase 3 | Gastric Cancer | - | - |
Giredestrant | Phase 3 | Endometrial Cancer | - | - |
Oseltamivir IV | Phase 3 | Influenza | - | - |
Sorafenib | Phase 3 | Carcinoma, Hepatocellular | - | - |
Interferon alfa 2a [Roferon] | Phase 3 | Renal Cell Cancer | - | - |
Disease-modifying anti-rheumatic drugs | Phase 3 | Rheumatoid Arthritis | - | - |
Becavizumab | Phase 3 | Hepatocellular Carcinoma | - | - |
Azathioprine | Phase 3 | Rheumatoid Arthritis | - | - |
Letrozole | Phase 3 | Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer | - | - |
Crizotinib | Phase 3 | Neoplasms | - | - |
Bitopertin | Phase 3 | Beta-Thalassemia | - | - |
Pegylated Interferon Alfa-2a | Phase 3 | Chronic Myelogenous Leukemia | - | - |
Pembrolizumab | Phase 3 | Non-small Cell Lung Cancer (NSCLC) | - | - |
Divarasib | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Rituximab SC | Phase 3 | Non-Hodgkin's Lymphoma | - | - |
saquinavir [Invirase] | Phase 3 | HIV Infections | - | - |
Optimized background antiretroviral regimen (OB) | Phase 3 | HIV Infections | - | - |
Permitted DMARDs | Phase 3 | Rheumatoid Arthritis | - | - |
Adalimumab | Phase 3 | Ulcerative Colitis | - | - |
exenatide | Phase 3 | Diabetes Mellitus Type 2 | - | - |
Ocrelizumab IV | Phase 3 | Relapsing Multiple Sclerosis | - | - |
bitopertin [RO4917838] level 1 | Phase 3 | Schizophrenia | - | - |
MTX | Phase 3 | Rheumatoid Arthritis | - | - |
Antipsychotics | Phase 3 | Schizophrenia | - | - |
Pegylated interferon (PEG-IFN) alfa-2a, 180 mcg | Phase 3 | Hepatitis B, Chronic | - | - |
Dacarbazine | Phase 3 | Malignant Melanoma | - | - |
rFVIIa | Phase 3 | Hemophilia A | - | - |
Taxotere | Phase 3 | Breast Cancer | - | - |
Fluoropyrimidine-based Chemotherapy | Phase 3 | Colorectal Cancer | - | - |
CDK4/6i | Phase 3 | Breast Cancer | - | - |
PDS Implant Pre-Filled with 100 mg/mL Ranibizumab | Phase 3 | Diabetic Retinopathy | - | - |
CMF | Phase 3 | Breast Cancer | - | - |
Doxorubicin | Phase 3 | Diffuse Large B-Cell Lymphoma, Lymphoma Follicular | - | - |
Stavudine | Phase 3 | HIV Infections | - | - |
temozolomide | Phase 3 | Glioblastoma Multiforme | - | - |
Ganciclovir | Phase 3 | Cytomegalovirus Retinitis | - | - |
tocilizumab SC | Phase 3 | Rheumatoid Arthritis | - | - |
Lamivudine | Phase 3 | HIV Infections | - | - |
PDS Implant with Ranibizumab 100 mg/mL | Phase 3 | Neovascular Age-Related Macular Degeneration | - | - |
Erlotinib | Phase 3 | Non-Squamous Non-Small Cell Lung Cancer | - | - |
satralizumab | Phase 3 | Neuromyelitis Optica Spectrum Disorder | - | - |
MMF | Phase 3 | Lupus Nephritis | - | - |
interferon-a-2a | Phase 3 | Lymphoma | - | - |
Baloxavir Marboxil | Phase 3 | Influenza | - | - |
TRO19622 | Phase 3 | Amyotrophic Lateral Sclerosis | - | - |
XELOX | Phase 3 | Colorectal Cancer | - | - |
Standard adjuvant chemotherapy | Phase 3 | Breast Cancer | - | - |
DMARD | Phase 3 | Rheumatoid Arthritis | - | - |
Sunitinib | Phase 3 | Renal Cell Carcinoma | - | - |
Mycophenolate Mofetil 2 g/Day | Phase 3 | Pemphigus Vulgaris (PV) | - | - |
Lebrikizumab | Phase 3 | Asthma | - | - |
Faricimab | Phase 3 | Wet Macular Degeneration | - | - |
Pegylated-interferon Alfa-2a | Phase 3 | Hepatitis C, Chronic | - | - |
Standard chemotherapy | Phase 3 | Breast Cancer | - | - |
von Willebrand Factor (VWF) Concentrates | Phase 3 | Von Willebrand Disease, Type 3 | - | - |
Oral Corticosteroids | Phase 3 | Rheumatoid Arthritis | - | - |
Prednisone | Phase 3 | Lymphoma | - | - |
valganciclovir [Valcyte] | Phase 3 | Cytomegalovirus Infections | - | - |
Acetaminophen/ Paracetamol | Phase 3 | Childhood Idiopathic Nephrotic Syndrome | - | - |
Corticosteroids | Phase 3 | Breast Cancer | - | - |
Antihistamine | Phase 3 | Multiple Sclerosis | - | - |
Lapatinib | Phase 3 | Breast Cancer | - | - |
epoetin | Phase 3 | Anemia | - | - |
Human Coagulation Factor VIII | Phase 3 | Hemophilia A | - | - |
Nab-paclitaxel | Phase 3 | Non-Small-Cell Lung | - | - |
fusidic acid [Verutex] | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Risdiplam | Phase 3 | Muscular Atrophy, Spinal | - | - |
Ocrelizumab | Phase 3 | Multiple Sclerosis | - | - |
Pegylated Interferon (PEG-IFN) alfa-2a | Phase 3 | Hepatitis D, Chronic | - | - |
Enzalutamide | Phase 3 | Prostatic Neoplasms, Castration-Resistant | - | - |
oseltamivir | Phase 3 | Influenza, Human | - | - |
Gemcitabine (Chemotherapy) | Phase 3 | Ovarian Cancer | - | - |
Second-Line Chemotherapy | Phase 3 | Non-Squamous Non-Small Cell Lung Cancer | - | - |
Nelfinavir mesylate | Phase 3 | HIV Infections | - | - |
Zalcitabine | Phase 3 | HIV Infections | - | - |
Efavirenz | Phase 3 | HIV Infections | - | - |
Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody | Phase 3 | Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer | - | - |
Etrozulimab | Phase 3 | Ulcerative Colitis | - | - |
Vinflunine | Phase 3 | Bladder Cancer | - | - |
Neoral | Phase 3 | Kidney Transplantation | - | - |
Gantenerumab | Phase 3 | Alzheimer's Disease | - | - |
PDS Implant filled with 100 mg/mL Ranibizumab | Phase 3 | Neovascular Age-Related Macular Degeneration | - | - |
Fulvestrant | Phase 3 | Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer | - | - |
anti-IL-2R | Phase 3 | Kidney Transplantation | - | - |
Endocrine Therapy of Physician's Choice | Phase 3 | Early Breast Cancer | - | - |
Delavirdine mesylate | Phase 3 | HIV Infections | - | - |
Chemotherapy (Induction Period) | Phase 3 | Non-Hodgkin's Lymphoma | - | - |
Fludarabine | Phase 3 | Lymphocytic Leukemia, Chronic | - | - |
tenofovir | Phase 3 | Hepatitis D, Chronic | - | - |
RO0503821 (1x/2 Weeks) | Phase 3 | Anemia | - | - |
pioglitazone | Phase 3 | Diabetes Mellitus Type 2 | - | - |
Olesoxime | Phase 3 | Muscular Atrophy, Spinal | - | - |
Riluzole | Phase 3 | Amyotrophic Lateral Sclerosis | - | - |
Astegolimab | Phase 3 | Chronic Obstructive Pulmonary Disease (COPD) | - | - |
Vinorelbine | Phase 3 | Non-Small Cell Lung Cancer | - | - |
bitopertin [RO4917838] | Phase 3 | Schizophrenia | - | - |
Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody | Phase 3 | Squamous Non-Small Cell Lung Cancer | - | - |
Mycophenolate mofetil (MMF) | Phase 3 | Lupus Nephritis | - | - |
5-Fluorouracil | Phase 3 | Gastric Cancer | - | - |
cyclosporine A (CsA) | Phase 3 | Heart Transplantation | - | - |
Bendamustine | Phase 3 | Chronic Lymphocytic Leukemia | - | - |
Platinum chemotherapy (cisplatin or carboplatin) | Phase 3 | Non-Squamous Non-Small Cell Lung Cancer | - | - |
Irinotecan | Phase 3 | Colorectal Cancer | - | - |
Pertuzumab IV | Phase 3 | Early Breast Cancer | - | - |
Venetoclax | Phase 3 | Chronic Lymphocytic Leukemia | - | - |
RO7234292 (RG6042) | Phase 3 | Huntington Disease | - | - |
Epirubicin | Phase 3 | Breast Cancer | - | - |
Regorafenib | Phase 3 | Colorectal Cancer | - | - |
Tacrolimus | Phase 3 | Primary Membranous Nephropathy | - | - |
trastuzumab [Herceptin] | Phase 3 | Breast Cancer | - | - |
Acitretin | Phase 3 | HIV Infections | - | - |
Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP) | Phase 3 | Diffuse Large B-Cell Lymphoma, Non-Hodgkin's Lymphoma | - | - |
Ranibizumab (10 mg/mL) | Phase 3 | Neovascular Age-related Macular Degeneration | - | - |
insulin glargine | Phase 3 | Diabetes Mellitus Type 2 | - | - |
Lenalidomide | Phase 3 | Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma | - | - |
Nonbiologic DMARDs of investigator's choice | Phase 3 | Rheumatoid Arthritis | - | - |
Tocilizumab 162 mg | Phase 3 | Rheumatoid Arthritis | - | - |
Optional Endocrine Therapy of Investigator's Choice | Phase 3 | Metastatic Breast Cancer | - | - |
Epoetin alfa | Phase 3 | Anemia | - | - |
5-Fluorouracil (5-FU) | Phase 3 | Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma | - | - |
Leucovorin calcium | Phase 3 | Colorectal Cancer | - | - |
5 FU | Phase 3 | Neoplasms | - | - |
Intravitreal Ranibizumab 0.5 mg Injection | Phase 3 | Diabetic Macular Edema | - | - |
Treatment of physician's choice | Phase 3 | Breast Cancer | - | - |
Oxaliplatin | Phase 3 | Colorectal Cancer | - | - |
montelukast [Singulair] | Phase 3 | Asthma | - | - |
Non-Biologic DMARDs | Phase 3 | Rheumatoid Arthritis | - | - |
rHuPH20 | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Tociluzumab | Phase 3 | Relapsed or Refractory Follicular Lymphoma | - | - |
Infliximab | Phase 3 | Ulcerative Colitis | - | - |
Fluorouracil | Phase 3 | Gastric Cancer | - | - |
Vemurafenib | Phase 3 | Melanoma | - | - |
Ipatasertib | Phase 3 | Triple-Negative Breast Cancer | - | - |
Ranibizumab | Phase 3 | Diabetic Macular Edema | - | - |
Emicizumab | Phase 3 | Hemophilia A | - | - |
Afimkibart | Phase 3 | Crohns Disease | - | - |
Docetaxel | Phase 3 | Non-Small Cell Lung Cancer | - | - |
tocilizumab [RoActemra/Actemra] | Phase 3 | Rheumatoid Arthritis | - | - |
Trastuzumab | Phase 3 | Breast Cancer | - | - |
Rituximab | Phase 3 | Rheumatoid Arthritis | - | - |
Atezolizumab | Phase 3 | Carcinoma, Hepatocellular | - | - |
Methoxy polyethylene glycol-epoetin beta (C.E.R.A.) | Phase 3 | Anemia | - | - |
Mircera | Phase 3 | Anemia | - | - |
erlotinib [Tarceva] | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Saquinavir | Phase 3 | HIV Infections | - | - |
Obinutuzumab | Phase 3 | Chronic Lymphocytic Leukemia (CLL) | - | - |
rituximab [MabThera/Rituxan] | Phase 3 | Rheumatoid Arthritis | - | - |
Cyclophosphamide | Phase 3 | Breast Cancer | - | - |
liposomal doxorubicin | Phase 3 | Ovarian Cancer | - | - |
Omalizumab | Phase 3 | Nasal Polyps | - | - |
csDMARDs | Phase 3 | Rheumatoid Arthritis | - | - |
pertuzumab [Perjeta] | Phase 3 | Breast Cancer | - | - |
tocilizumab | Phase 3 | Rheumatoid Arthritis | - | - |
bevacizumab [Avastin] | Phase 3 | Non-Squamous Non-Small Cell Lung Cancer | - | - |
ritonavir | Phase 3 | HIV Infections | - | - |
Etrolizumab | Phase 3 | Crohn Disease | - | - |
leucovorin | Phase 3 | Colorectal Cancer | - | - |
Epoetin beta | Phase 3 | Anemia | - | - |
Lurbinectedin | Phase 3 | Small-Cell Lung Cancer | - | - |
taspoglutide | Phase 3 | Diabetes Mellitus Type 2 | - | - |
Bevacizumab | Phase 3 | Carcinoma, Hepatocellular | - | - |
Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody | Phase 3 | Triple-Negative Breast Cancer | - | - |
Ibandronate | Phase 3 | Post-Menopausal Osteoporosis | - | - |
methotrexate | Phase 3 | Rheumatoid Arthritis | - | - |
Entrectinib | Phase 3 | Solid Tumors | - | - |
peginterferon alfa-2a [Pegasys] | Phase 3 | Hepatitis B, Chronic | - | - |
Methoxy Polyethylene Glycol-Epoetin Beta | Phase 3 | Anemia | - | - |
mycophenolate mofetil (CellCept) | Phase 3 | Myasthenia Gravis, Generalized | - | - |
Onartuzumab | Phase 3 | Glioblastoma | - | - |
Pirfenidone | Phase 3 | Lung Diseases, Interstitial | - | - |
Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody | Phase 3 | Carcinoma, Non-Squamous Non-Small Cell Lung | - | - |
Capecitabine | Phase 3 | Gastric Cancer | - | - |
Fixed Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Use (PH FDC SC) | Phase 3 | Early Breast Cancer | - | - |
Trastuzumab IV | Phase 3 | HER2-positive Early Breast Cancer | - | - |
Other Combination Anti-Cancer Therapies | Phase 3 | Solid Tumors | - | - |
Valganciclovir | Phase 3 | Cytomegalovirus Infections | - | - |
Filgrastim | Phase 3 | Triple-negative Breast Cancer | - | - |
methoxy polyethylene glycol-epoetin beta [Mircera] | Phase 3 | Anemia | - | - |
Herceptin | Phase 3 | Breast Cancer | - | - |
Trastuzumab Emtansine | Phase 3 | Breast Cancer | - | - |
Gemcitabine | Phase 3 | Pancreatic Cancer | - | - |
Fenebrutinib | Phase 3 | Relapsing Multiple Sclerosis | - | - |
Dexamethasone | Phase 3 | Idiopathic Thrombocytopenic Purpura | - | - |
Glofitamab | Phase 3 | Diffuse Large B-cell Lymphoma | - | - |
Alectinib | Phase 3 | Non-Small Cell Lung Cancer | - | - |
capecitabine [Xeloda] | Phase 3 | Colorectal Cancer | - | - |
Peginterferon alfa-2a | Phase 3 | Carcinoma, Hepatocellular | - | - |
Cladribine | Phase 3 | Lymphocytic Leukemia, Chronic | - | - |
metformin | Phase 3 | Diabetes Mellitus Type 2 | - | - |
ibandronate [Bonviva/Boniva] | Phase 3 | Post-Menopausal Osteopenia | - | - |
Trontinemab | Phase 3 | Alzheimers Disease | - | - |
Aflibercept | Phase 3 | Diabetic Macular Edema | - | - |
RO7239361 | Phase 3 | Duchenne Muscular Dystrophy | - | - |
Sitagliptin | Phase 3 | Diabetes Mellitus Type 2 | - | - |
aleglitazar | Phase 3 | Diabetes Mellitus Type 2 | - | - |
Alectnib | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
Chemotherapy | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Inavolisib | Phase 3 | Breast Cancer | - | - |
Leucovorin (LV) | Phase 3 | Colorectal Cancer | - | - |
CHOP | Phase 3 | Lymphoma, Large B-Cell, Diffuse | - | - |
rituximab [MabThera] | Phase 3 | Rheumatoid Arthritis | - | - |
RO4917838 | Phase 3 | Schizophrenia | - | - |
Baseline Treatment | Phase 3 | Neuromyelitis Optica (NMO) | - | - |
Acetaminophen/Paracetamol | Phase 3 | Systemic Lupus Erythematosus | - | - |
Phesgo | Phase 3 | Locally Advanced or Metastatic Breast Cancer | - | - |
Fludarabine Phosphate | Phase 3 | Chronic Lymphocytic Leukemia | - | - |
methoxy polyethylene glycol-epoetin beta [C.E.R.A.] | Phase 3 | Anemia | - | - |
Pemetrexed | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
Ortho-Novum® 1/35 | Phase 3 | Rheumatoid Arthritis | - | - |
PEGASYS | Phase 3 | Hepatitis C, Chronic | - | - |
Cisplatin | Phase 3 | Nasopharyngeal Cancer | - | - |
orlistat [Xenical] | Phase 3 | Obesity | - | - |
aleglitazar+metformin | Phase 3 | Diabetes Mellitus Type 2 | - | - |
dalcetrapib | Phase 3 | Coronary Heart Disease | - | - |
Palbociclib | Phase 3 | Breast Cancer | - | - |
Tiragolumab and Atezolizumab | Phase 3 | Cancer | - | - |
Cobimetinib | Phase 3 | Melanoma | - | - |
DMARDs | Phase 3 | Rheumatoid Arthritis | - | - |
MabThera/Rituxan | Phase 3 | Rheumatoid Arthritis | - | - |
RO7234292 | Phase 3 | Huntingtons Disease | - | - |
Onartuzumab [MetMAb] | Phase 3 | Non-Small Cell Lung Cancer | - | - |
epoetin beta [NeoRecormon] | Phase 3 | Anemia | - | - |
Crovalimab | Phase 3 | Atypical Hemolytic Uremic Syndrome | - | - |
Dual Integrin Antagonist | Phase 2 | Asthma | - | - |
RO4917523 1.5 mg | Phase 2 | Major Depressive Disorder | - | - |
Semaglutide | Phase 2 | Type 2 Diabetes Mellitus | - | - |
Atezolizumab Cohort 7 | Phase 2 | Solid Tumors | - | - |
boceprevir | Phase 2 | Hepatitis C, Chronic | - | - |
Abemaciclib | Phase 2 | Ovarian Cancer | - | - |
RO7247669 | Phase 2 | Melanoma | - | - |
enfuvirtide [Fuzeon] | Phase 2 | HIV Infections | - | - |
Tiragolumab and Atezolizumab IV FDC | Phase 2 | PD-L1-selected Solid Tumors | - | - |
Ro 24-7429 | Phase 2 | Sarcoma, Kaposi | - | - |
RG7314 | Phase 2 | Autism Spectrum Disorder | - | - |
Tociliuzumab | Phase 2 | COVID-19 Pneumonia | - | - |
TCS Cream | Phase 2 | Atopic Dermatitis | - | - |
Tobemstomig | Phase 2 | Urothelial Cancer | - | - |
antibody induction | Phase 2 | Kidney Transplantation | - | - |
Onartuzumab (MetMAb) | Phase 2 | Gastric Cancer | - | - |
Standard antipsychotic therapy | Phase 2 | Schizophrenia | - | - |
RO6864018 | Phase 2 | Hepatitis B, Chronic | - | - |
RO5093151 | Phase 2 | Hypertension, Glaucoma, Open-Angle | - | - |
Induction- PF-06480605 50 mg SC Q4W | Phase 2 | Moderate to Severe Ulcerative Colitis | - | - |
RO7268489 | Phase 2 | Progressive Multiple Sclerosis | - | - |
LABA | Phase 2 | Asthma | - | - |
vismodegib | Phase 2 | Basal Cell Carcinoma | - | - |
RO4588161 | Phase 2 | Hepatitis C, Chronic | - | - |
PEGPH20 | Phase 2 | Pancreatic Adenocarcinoma | - | - |
FOLFIRI | Phase 2 | Colorectal Cancer | - | - |
Olaparib | Phase 2 | Cancer of Unknown Primary Site | - | - |
RO4998452 | Phase 2 | Diabetes Mellitus Type 2 | - | - |
RO4602522 | Phase 2 | Alzheimer's Disease | - | - |
ribavirin [Copegus] | Phase 2 | Hepatitis C, Chronic | - | - |
Everolimus | Phase 2 | Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer | - | - |
Zifibancimig | Phase 2 | Macular Degeneration | - | - |
Anastrozole | Phase 2 | Early Breast Cancer | - | - |
Mericitabine | Phase 2 | Hepatitis C | - | - |
Lomustine | Phase 2 | Glioblastoma | - | - |
Induction Chemotherapy | Phase 2 | Breast Cancer | - | - |
AT-527 | Phase 2 | COVID-19 | - | - |
Olesoxime (TRO19622) | Phase 2 | Chemotherapy-Induced Peripheral Neuropathy | - | - |
capecitabine (Xeloda®) | Phase 2 | Breast Cancer | - | - |
Standard platinum-based chemotherapy | Phase 2 | Non-Small Cell Lung Cancer | - | - |
SGN-LIV1A | Phase 2 | Metastatic Breast Cancer | - | - |
Actos | Phase 2 | Diabetes Mellitus Type 2 | - | - |
bevacizumab (Avastin) | Phase 2 | Liver Cancer | - | - |
First line chemotherapy | Phase 2 | Mantle Cell Lymphoma | - | - |
Folic Acid | Phase 2 | Rheumatoid Arthritis | - | - |
Erythropoietin Beta | Phase 2 | Myelodysplastic Syndromes | - | - |
PRM-151 | Phase 2 | Idiopathic Pulmonary Fibrosis | - | - |
RO7126209 | Phase 2 | Alzheimers Disease | - | - |
Metronidazole Actavis | Phase 2 | Non-Squamous Non-Small Cell Lung Cancer | - | - |
Tominersen | Phase 2 | Huntington Disease | - | - |
RO5027838 | Phase 2 | Diabetes Mellitus Type 2 | - | - |
RO7490677 | Phase 2 | Primary Myelofibrosis | - | - |
Mycophenolate Mofetil/Mycophenolic Acid | Phase 2 | Lupus Nephritis | - | - |
RO5313534 | Phase 2 | Alzheimer's Disease | - | - |
RO6889450 | Phase 2 | Schizophrenia, Schizoaffective Disorder | - | - |
Epidoxorubicin | Phase 2 | Breast Cancer | - | - |
Balovaptan | Phase 2 | Stress Disorders, Post-Traumatic | - | - |
Carboplatin-based chemotherapy | Phase 2 | Non-Small Cell Lung Cancer | - | - |
Pegylated Interferon (Peginterferon) Alfa-2a | Phase 2 | Hepatitis B, Chronic | - | - |
Pravastatin | Phase 2 | Dyslipidemia | - | - |
Lomvastomig | Phase 2 | Advanced or Metastatic Esophageal Squamous Cell Carcinoma | - | - |
RG3421 120mg | Phase 2 | Psoriasis | - | - |
Standard taxane therapy | Phase 2 | Breast Cancer | - | - |
Doxycline | Phase 2 | Non-Small Cell Lung Cancer | - | - |
Ifosfamide | Phase 2 | Mature B-Cell Non-Hodgkin Lymphoma | - | - |
obinutuzumab (RO5072759) | Phase 2 | Non-Hodgkin's Lymphoma | - | - |
Iberdomide | Phase 2 | Multiple Myeloma | - | - |
RO5083945 | Phase 2 | Non-Squamous Non-Small Cell Lung Cancer | - | - |
GC33 | Phase 2 | Carcinoma, Hepatocellular | - | - |
fluorouracil (5FU) | Phase 2 | Colorectal Cancer | - | - |
RO5217790 | Phase 2 | Cervical Intraepithelial Neoplasia | - | - |
RO4917523 | Phase 2 | Fragile X Syndrome | - | - |
pralsetinib (BLU-667) | Phase 2 | RET-altered Non Small Cell Lung Cancer | - | - |
5-FU | Phase 2 | Colorectal Cancer | - | - |
ibandronate [Bondronat] | Phase 2 | Pain; Bone Neoplasms; Neoplasm Metastasis | - | - |
Mosunetuzumab (SC) | Phase 2 | Follicular Lymphoma | - | - |
RO4876904 | Phase 2 | Diabetes Mellitus Type 2 | - | - |
Crenezumab | Phase 2 | Alzheimer Disease | - | - |
Cevostamab | Phase 2 | Multiple Myeloma | - | - |
RO4917523 0.5 mg | Phase 2 | Fragile X Syndrome | - | - |
Erlotinib, escalating dose | Phase 2 | Pancreatic Cancer | - | - |
eloxatin | Phase 2 | Colorectal Cancer | - | - |
ANA598 | Phase 2 | HCV Infection | - | - |
Copegus | Phase 2 | Hepatitis C, Chronic | - | - |
N-acetylcysteine | Phase 2 | Idiopathic Pulmonary Fibrosis | - | - |
OpRegen | Phase 2 | Age-Related Macular Degeneration | - | - |
Basmisanil | Phase 2 | Schizophrenia | - | - |
TRO40303 | Phase 2 | Acute Myocardial Infarctus | - | - |
RG7774 | Phase 2 | Diabetic Retinopathy | - | - |
RO7795081 | Phase 2 | Obesity or Overweight | - | - |
RO5190591 (Danoprevir) | Phase 2 | Hepatitis C, Chronic | - | - |
RO4995819 | Phase 2 | Major Depressive Disorder | - | - |
Abiraterone | Phase 2 | Metastatic Castration-Resistant Prostate Cancer | - | - |
P38 Inhibitor (4) 150mg | Phase 2 | Rheumatoid Arthritis | - | - |
Forimtamig | Phase 2 | Relapsed or Refractory Multiple Myeloma | - | - |
Inhaled corticposteroids (ICS) | Phase 2 | Asthma | - | - |
Experimental | Phase 2 | Diabetic Neuropathy | - | - |
fotemustine | Phase 2 | Glioblastoma Multiforme | - | - |
Investigator's choice of anti-cancer treatment (except immunotherapy) | Phase 2 | Breast Cancer | - | - |
Sham Procedure | Phase 2 | Neovascularization, Choroidal | - | - |
Atezolizumab [TECENTRIQ] | Phase 2 | Lymphoma | - | - |
Optimized Background ARVs | Phase 2 | HIV Infections | - | - |
Trastuzumab emtansine [Kadcyla] | Phase 2 | Breast Cancer | - | - |
Abacavir sulfate | Phase 2 | HIV Infections | - | - |
RO4905417 | Phase 2 | Coronary Heart Disease, Graft Occlusion, Vascular | - | - |
Taxane (docetaxel or paclitaxel) | Phase 2 | Breast Cancer | - | - |
RO5190591 | Phase 2 | Hepatitis C, Chronic | - | - |
Temozolomide (TMZ) | Phase 2 | High Grade Glioma | - | - |
Sildenafil | Phase 2 | Idiopathic Pulmonary Fibrosis | - | - |
NXT007 | Phase 2 | Hemophilia A | - | - |
RO5459072 | Phase 2 | Sjogren's Syndrome | - | - |
RAR Gamma | Phase 2 | Emphysema | - | - |
Alogabat | Phase 2 | Angelman Syndrome | - | - |
89Zr-Df-IAB22M2C | Phase 2 | Non-Hodgkins Lymphoma | - | - |
beta-lactam | Phase 2 | Soft Tissue Infections | - | - |
RO5185426 | Phase 2 | Malignant Melanoma | - | - |
Mosunetuzumab Intravenous (IV) | Phase 2 | Diffuse Large B-cell Lymphoma | - | - |
Englumafusp alfa | Phase 2 | Lymphoma, Non-Hodgkin | - | - |
Rituxumab | Phase 2 | B-cell Non-Hodgkin Lymphoma | - | - |
SSRI | Phase 2 | Obsessive-Compulsive Disorder | - | - |
RO7269162 | Phase 2 | Alzheimer's Disease | - | - |
Polatuzumab vedotin (Liquid) | Phase 2 | Lymphoma | - | - |
Ribociclib | Phase 2 | Breast Cancer | - | - |
RO7247669 2100 mg | Phase 2 | Melanoma | - | - |
Ocrelizumab Test Formulation | Phase 2 | Multiple Sclerosis | - | - |
Xeloda | Phase 2 | Breast Cancer | - | - |
C.E.R.A. | Phase 2 | Anemia | - | - |
cetuximab | Phase 2 | Multiple Myeloma, Neoplasms | - | - |
Taspoglutide 20mg | Phase 2 | Diabetes Mellitus Type 2 | - | - |
Mosunetuzumab (IV) | Phase 2 | B-cell Non-Hodgkin Lymphoma | - | - |
RO6958688 | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody | Phase 2 | Breast Neoplasms | - | - |
Trastuzumab emtansine [Kadcyla] 3.0 mg/kg | Phase 2 | Metastatic Breast Cancer | - | - |
RO4929097 | Phase 2 | Non-Squamous Non-Small Cell Lung Cancer | - | - |
P38 Inhibitor (4) | Phase 2 | Rheumatoid Arthritis | - | - |
Ceftriaxone | Phase 2 | Pneumonia, Bacterial | - | - |
Didanosine | Phase 2 | HIV Infections | - | - |
Folinic Acid | Phase 2 | Rectal Cancer | - | - |
Levofolinic acid | Phase 2 | Colorectal Cancer | - | - |
Autogene Cevumeran | Phase 2 | Muscle-invasive Urothelial Carcinoma | - | - |
danoprevir + ritonavir | Phase 2 | Hepatitis C, Chronic | - | - |
Epothilone D | Phase 2 | Breast Cancer | - | - |
Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC) | Phase 2 | HER2-Positive Early Breast Cancer | - | - |
Interferon alfa-2a | Phase 2 | Renal Cell Cancer | - | - |
ZN-A-1041 | Phase 2 | Advanced Solid Tumors | - | - |
Axitinib | Phase 2 | Renal Cell Carcinoma | - | - |
Nucleos(t)ide (NUC) | Phase 2 | Hepatitis B, Chronic | - | - |
GK Activator (2) | Phase 2 | Diabetes Mellitus Type 2 | - | - |
Second line chemotherapy | Phase 2 | Breast Cancer | - | - |
RG1662 | Phase 2 | Down Syndrome | - | - |
Rituximab IV | Phase 2 | Lymphoma, Large B-Cell, Diffuse | - | - |
Fulvestrant or an Aromatase Inhibitor (Physician Choice) | Phase 2 | Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer | - | - |
RO7046015 | Phase 2 | Parkinson's Disease | - | - |
Atezolizumab (MPDL3280A) [TECENTRIQ] | Phase 2 | Lymphoma, Follicular | - | - |
Aromatase Inhibitor | Phase 2 | Breast Cancer | - | - |
Diphenhydramine hydrochloride (HCl) | Phase 2 | Lupus Nephritis | - | - |
Hormonal Therapy | Phase 2 | Breast Cancer | - | - |
DPP-IV Inhibitor | Phase 2 | Diabetes Mellitus Type 2 | - | - |
Enfortumab Vedotin | Phase 2 | Urothelial Carcinoma | - | - |
PEGASYS [peginterferon alfa-2a] | Phase 2 | Hepatitis B, Chronic | - | - |
MSTT1041A | Phase 2 | Asthma | - | - |
RO7017773 | Phase 2 | Autism Spectrum Disorder (ASD) | - | - |
RO 205-2349 | Phase 2 | Diabetes | - | - |
Danoprevir | Phase 2 | Hepatitis C, Chronic | - | - |
Bevacizumab 15 mg/kg | Phase 2 | Advanced Liver Cancers | - | - |
RO5024048 | Phase 2 | Hepatitis C, Chronic | - | - |
Breast Cancer
1 drug in this indication
Duchenne Muscular Dystrophy
1 drug in this indication
Obesity
1 drug in this indication
Myasthenia Gravis Generalised
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)